SHORT MINI-FUTURE - ELI LILLY & CO | Delayed Deutsche Boerse AG 04:31:37 2024-05-22 EDT | ||
| 16.75 EUR | -0.24% |
|
| Current month | -13.41% | ||
| 1 month | -30.19% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-05-22 | 16.75 | -0.24% |
| 24-05-21 | 16.79 | -11.21% |
| 24-05-20 | 18.91 | -4.74% |
| 24-05-17 | 19.85 | +2.16% |
| 24-05-16 | 19.43 | +1.83% |
Delayed Quote Deutsche Boerse AG
Last update May 22, 2024 at 04:31 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VD0KLL |
| ISIN | DE000VD0KLL2 |
| Date issued | 2024-02-19 |
| Strike | 987.1 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 19.04 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 24.66 € |
|---|---|
| Lowest since issue | 16.67 € |
| Spread | 0.19 € |
| Spread % | 1.12% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
803.2
USD
Average target price
850.4
USD
Spread / Average Target
+5.88%
- Stock Market
- Certificates
- Certificat
